EP08.02-158 Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC

Docetaxel is one of the standard 2nd-line treatments for advanced non-small cell lung cancer (NSCLC), but the effect is limited. The combination of docetaxel and ramucirumab/nintedanib has demonstrated antitumor activity as 2nd-line therapy in advanced NSCLC. Anlotinib, an oral multi-target angiogenesis, can prolong both PFS and OS of refractory advanced NSCLC patients in phase III trial (ALTER0303). We conducted ALTER-L018 to evaluate improvement of the efficacy and safety of anlotinib plus docetaxel in EGFR-negative advanced NSCLC.